1627911-44-7
Chemical Structure
CS-6253
- CAS No.: 1627911-44-7
- Formula:C136H228N36O43
- Molecular Weight:3055.48
SMILES: C([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCC(O)=O)N)=O)C(C)C)=O)CCCNC(N)=O)=O)CO)=O)CCCCN)=O)CC(C)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CO)=O)CCCCN)=O)CC(C)C)=O)CCCNC(=N)N)=O)C)=O)CC(C)C)=O)CC(C)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)C)=O)CC(C)C)=O)CCC(O)=O)=O)CCCNC(N)=O)=O)CC(C)C)=O)C)=O)C)=O)CC(C)C)=O)C=1C=2C(NC1)=CC=CC2
Biological Activity: CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CS-6253 | 98.84% | CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hafiane A, et al. ABCA1 Agonist Mimetic Peptide CS-6253 Induces Microparticles Release From Different Cell Types by ABCA1-Efflux-Dependent Mechanism. Can J Cardiol. 2019 Jun;35(6):770-781. [Content Brief]
- [2]. Noveir SD, et al. Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys. Alzheimers Res Ther. 2022 Jun 24;14(1):87. [Content Brief]
- [3]. Boehm-Cagan A, et al. ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies. J Alzheimers Dis. 2016 Oct 4;54(3):1219-1233. [Content Brief]
